Skip to main content
TipRanks
Go Ultimate75% OFF

Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) AI Stock Analysis

2 Followers
HK:6609

Shanghai Heartcare Medical Technology Corp. Ltd. Class H

(HKEX:6609)

Select Model
Rating:79Outperform
Price Target:HKD 59.00â–²(15.01% Upside)
Action:reiterated
Date:10/08/26

Strong financial performance from rapid revenue growth and path to profitability is the primary driver. Bullish technical indicators reinforce positive momentum, while fair valuation supports the score.

Positive Factors
Revenue ExpansionRevenue has expanded dramatically over several years, indicating that the company has materially increased its commercial scale. A larger revenue base can support operating leverage, broaden the platform for cardiovascular products, and provide greater capacity to fund continued business development.
Negative Factors
Profitability VolatilityThe return to profit is recent and follows several years of substantial losses, including 2024. This history indicates that earnings power has not yet been demonstrated consistently across reporting periods, making future profitability more sensitive to execution and business conditions.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) vs. iShares MSCI Hong Kong ETF (EWH)

-20%-10%0%10%20%30%40%HK:6609+10.56%EWH+9.24%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 1.98B
Dividend Yield
―
Average Volume (3M)
46.75K
Price to Earnings (P/E)
17.6
Beta (1Y)
0.72
Revenue Growth
59.30%
EPS Growth
131.03%
Country
Hong Kong
Employees
425
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Business Overview & Revenue Model

Company Description

Shanghai HeartCare Medical Technology Corporation Limited is a global enterprise specializing in the research, development, manufacturing, and commercialization of neuro-interventional medical devices. Its extensive product range encompasses devices...

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Financial Statement Overview

Summary

Robust revenue growth from $14.6M to projected $397.7M by 2025, gross margins to 69%, shift to 20% net margin and positive cash flow, with low debt supporting stability.

Income Statement

85Very Positive

Balance Sheet

80Positive

Cash Flow

75Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue513.79M408.29M277.90M232.34M183.03M90.09M
Gross Profit353.55M272.17M181.72M151.79M124.33M54.95M
EBITDA113.69M72.56M21.87M-68.50M-167.31M-183.34M
Net Income92.76M83.33M-13.62M-94.01M-200.38M-194.22M
Balance Sheet
Total Assets1.37B1.29B1.21B1.20B1.31B1.50B
Cash, Cash Equivalents and Short-Term Investments789.70M786.81M713.72M721.14M870.12M1.22B
Total Debt41.22M42.74M35.75M36.38M50.69M41.94M
Total Liabilities152.73M133.50M144.00M125.60M147.08M132.10M
Stockholders Equity1.22B1.13B1.06B1.08B1.17B1.37B
Cash Flow
Free Cash Flow97.61M139.98M-8.39M-137.72M-304.01M-260.33M
Operating Cash Flow105.51M154.14M-3.23M-88.41M-266.77M-205.85M
Investing Cash Flow-90.02M-253.09M10.80M-125.45M44.84M-161.10M
Financing Cash Flow-31.71M-44.73M-12.38M-21.48M-24.75M821.25M

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Technical Analysis

Technical Analysis SentimentPositive
Last Price51.30

Price Trends

50DMA52.43Negative
100DMA49.55Positive
200DMA48.92Positive

Market Momentum

MACD-0.68Negative
RSI50.16Neutral
STOCH81.97Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6609, the sentiment is Positive. The current price of 51.30 is above the 20-day moving average (MA) of 50.87, below the 50-day MA of 52.43, and above the 200-day MA of 48.92, indicating a neutral trend. The MACD of -0.68 indicates Negative momentum. The RSI at 50.16 is Neutral, neither overbought nor oversold. The STOCH value of 81.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6609.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:6609 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:6609HK:660979OutperformHKD 2.10B17.577.90%―59.30%131.03%
HK:1302HK:130262NeutralHKD 6.26B96.951.71%―0.75%-20.22%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:9996HK:999645NeutralHKD 2.50B-14.85-7.65%―21.23%36.89%
HK:2500HK:250044NeutralHKD 427.78M-0.78-28.24%―-38.15%25.70%
HK:2160HK:216043NeutralHKD 1.63B-0.86-6.69%―――
HK:0853HK:085341NeutralHKD 11.65B31.226.07%―-3.62%―

* Healthcare Sector Average

Performance Comparison

-50%0%HK:6609HK:0853HK:9996HK:1302HK:2160HK:2500Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:6609 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:6609Shanghai Heartcare Medical Technology Corp. Ltd. Class H51.305.1811.23%
HK:0853MicroPort Scientific Corp6.08-4.35-41.75%
HK:9996Peijia Medical Ltd.3.69-1.85-33.42%
HK:1302LifeTech Scientific Corporation1.45-0.35-19.44%
HK:2160MicroPort CardioFlow Medtech Corp.1.28-4.42-77.54%
HK:2500Venus Medtech (Hangzhou), Inc. Class H0.97-1.43-59.58%

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Corporate Events

Shanghai HeartCare Sets Postponed EGM for November 26, 2026

Nov 11, 2026

Shanghai HeartCare Medical Technology Corporation Limited issued a supplemental notice for its postponed 2026 third extraordinary general meeting, which will be held in Shanghai on November 26, 2026. The meeting will consider three-year appointments...

HeartCare Announces Director Retirement and Proposed Executive Appointment

Nov 9, 2026

Shanghai HeartCare Medical Technology Corporation said non-executive director Chen Gang will retire and will not seek re-election because of other work arrangements. He will also leave the board’s strategy committee, with the company stating that he...

Shanghai HeartCare Calls 2026 EGM to Reset Board Line-up and Pay

Oct 29, 2026

Shanghai HeartCare Medical Technology Corporation Limited has convened its third extraordinary general meeting for 2026 on November 13 in Shanghai to vote on a slate of board appointments and reappointments. The resolutions cover executive, non-execu...

Shanghai HeartCare Proposes New Board Term and Adds Non-Executive Director

Oct 26, 2026

Shanghai HeartCare Medical Technology Corporation Limited has initiated the process to form its third session of the board of directors, as the current second session is due to expire in November 2026. The proposed new board will comprise nine direct...

Shanghai HeartCare Ties New H Share Incentive Grant to Aggressive Revenue Growth Targets

Sep 21, 2026

Shanghai HeartCare Medical Technology Corporation Limited has granted 30,000 H share awards, equal to about 0.10% of its issued H shares, to a single employee under its 2025 H Share Incentive Scheme. The awards carry no issue price and are structured...

Shanghai HeartCare Grants Performance-Tied H Share Awards to Boost Growth

Sep 14, 2026

Shanghai HeartCare Medical Technology Corporation Limited, a Hong Kong-listed cardiovascular medical technology provider, is deepening its focus on talent retention and performance-driven culture through equity incentives. The company operates in the...

Shanghai HeartCare Details Voting Results and Governance at 2026 Second EGM

Sep 3, 2026

Shanghai HeartCare Medical Technology Corporation Limited reported that its 2026 second extraordinary general meeting was duly convened in Shanghai in accordance with PRC company law and its articles of association, with all directors attending eithe...

Shanghai HeartCare Delivers Robust Interim Growth on Expanding Stroke Device Adoption

Aug 31, 2026

Shanghai HeartCare Medical Technology reported strong interim results for the six months ended June 30, 2026, with revenue rising 56.9% to RMB291 million and gross profit climbing 64.3% amid margin expansion. Net profit attributable to shareholders g...

Shanghai HeartCare Sets August Board Meeting to Review Interim Results and Dividend

Aug 19, 2026

Shanghai HeartCare Medical Technology Corporation Limited has scheduled a board meeting for August 31, 2026 to review and approve the interim results for the six months ended June 30, 2026 for the company and its subsidiaries. The board will also con...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 08, 2026